|
Russian Heart Days 2021 – The view of a Young Scientists Authors: Lyapina Irina Nikolaevna – PhD, MD, researcher of laboratory of rehabilitation of clinical cardiology department of Scientific Research Institute for Complex issues of cardiovascular diseases, The Chairman of working group «Young cardiologists» of Russian Society of Cardiology, Kemerovo Chichkova Tat’iana Yurievna- PhD, MD, researcher of laboratory of heart rhythm disorders and electrocardiostimulation of the department of heart and vessels surgery of Scientific Research Institute for Complex issues of cardiovascular diseases, Kemerovo Teplova Yulia Eugenievna– PhD student, laboratory research assistant of laboratory of heart defects of the department of heart and vessels surgery of Scientific Research Institute for Complex issues of cardiovascular diseases, Kemerovo
For the first time after a long period of exclusively online events, a face-to-face meeting with the luminaries of Russian cardiology, an opportunity to take part in a discussion and exchange of experience with leading specialists of the European Society of Cardiology, was presented to us by the VIII International Educational Forum "Russian Heart Days", held on April 22-24 in a magical city St. Petersburg. We were particularly impressed by the scale of the event and the successful implementation of the hybrid format of the Forum.
339 specialists had the opportunity to attend the event in person, and more than 2000 people followed the online broadcasts. The program of the forum was very rich. Leading scientists from France, the Netherlands, Sweden, Germany, Serbia, Great Britain and, of course, Russian Federation shared their experience. Many clinical cases were analyzed in the light of the updated recommendations of the European Society of Cardiology, in addition, the issues of treatment of many cardiac pathologies were highlighted, and the results of current research were presented. Special emphasis was placed on new treatment options for patients with chronic heart failure (CHF). So, in their reports, Professor Jeroen Bax (the Netherlands) and Professor Svetlana Villewalde (St. Petersburg) presented the results of a randomized placebo-controlled clinical trial VICTORIA. This study highlighted the role of a novel stimulator of soluble guanylate cyclase, vericiguat, in a cohort of very high-risk severe patients with reduced ejection fraction, recently hospitalized for decompensation of HF, or on intravenous diuretic therapy with insufficient response to therapy. The addition of vericiguat to standard CHF therapy resulted in a statistically significant reduction in the number of hospitalizations and mortality in this cohort of patients [1].
In addition, Professor Jeroen Bax, in his report "The most significant innovations in Cardiology in 2020", presented the results of treatment with sodium-glucose cotransporter (SGLT2) inhibitors-empagliflozin in the EMPEROR-REDUCED study and dapagliflozin in the DAPA-HF study. Thus, the use of empagliflozin as well as dapagliflozin in patients with HF and a low left ventricular ejection fraction, regardless of the presence of diabetes mellitus, demonstrated a significant reduction in all-cause mortality by 13% and cardiovascular mortality by 14%, also reducing the risk of repeated hospitalizations for decompensation of HF and the risk of deterioration of renal function [2].
1 |
